Search Results 541-550 of 16796 for GLP-1 agonists
Eligibility last updated 11/1/22. Questions regarding updates should be directed to the study team contact. Participating Mayo Clinic locations. Study ...
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Abciximab; Acenocoumarol ...
Julie Ferris-Tillman, Ph.D. January 21, 2026. New CT imaging oral contrast agent improves visualization of bowel anatomy, clinical trial ...
Avelumab In Combination Regimens That Include An Immune Agonist ... PTT-936, an Alpha Kinase 1 (ALPK1) Activator ... And I think that is one of the ...
Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome ...
Keep this container away from children and pets. You might not use all of the medicine in each vial or syringe. Use single-use vial or syringe only one time. Do ...
Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6- ...
... 1 of glucose had about twice as much 14C as carbon 3. Carbon 2 of glutamate had about twice as much 14C as carbon 1 and one-half to one-third as much as carbon ...
One uncontrolled, unpublished study suggests that a footstool improved bowel ... 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) who are ...
About this study. To evaluate the effectiveness of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02:01, ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!